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Vitamin D Deficiency or Supplementation and the 
Risk of Human Herpesvirus Infections or Reactivation: 
A Systematic Review and Meta-analysis
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Background. Vitamin D may protect against respiratory virus infections, but any association with herpesviruses is unclear.
Methods. We undertook a systematic review of vitamin D deficiency or supplementation and the risk of 8 human herpesviruses. Six 
databases and 4 gray literature databases were searched for relevant cohort studies, case–control studies, and clinical trials.
Results. Ten studies were included, all conducted among immunosuppressed patients. There was no evidence that vitamin D 
deficiency is associated with cytomegalovirus (CMV) disease (pooled risk ratio, 1.06; 95% CI, 0.66–1.7), herpes zoster after trans-
plantation (1 study), or HHV-8 among HIV patients (1 study). Vitamin D supplementation may decrease herpes zoster among 
hemodialysis patients (1 study) or CMV disease after renal transplantation (1 study), but supplementation was not associated with 
reduced EBV viral load among multiple sclerosis patients (1 study).
Conclusions. Any association between vitamin D and herpesviruses remains inconclusive. Further studies in the general pop-
ulation are needed.
Keywords. cytomegalovirus; Epstein-Barr virus; herpes zoster; herpesviridae; systematic review; vitamin D deficiency; vitamin 
D supplementation.
Herpesviruses are a family of 8 DNA viruses that induce life-
long latency after infecting humans; they include herpes 
simplex virus type 1 and type 2 (HSV-1 and HSV-2), varicella-
zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus 
(CMV), HHV-6, HHV-7, and Kaposi’s sarcoma–associated 
herpesvirus (KSHV). These viruses can reactivate and lead to 
clinical symptoms when the immunity of the host declines [1]. 
Although many primary herpesvirus infections are mild or 
self-limited, both infection and reactivation may lead to rare 
but serious complications that affect quality of life and lead to 
a substantial burden on health care services. For example, VZV 
causes chickenpox among children and herpes zoster in adults. 
Especially among people older than age 65  years, zoster may 
lead to post-herpetic neuralgia, which is associated with an in-
creased risk of cardiovascular outcomes and financial burden 
[2, 3]. CMV infection is usually asymptomatic in healthy adults, 
but infection of immunocompromised hosts can lead to graft 
loss or death [4]. Consequently, it is important to explore the 
immunomodulatory factors associated with infection or reac-
tivation of herpesviruses.
Vitamin D is synthesized by the skin after sunlight exposure, 
or it can also be consumed through food or supplements. Its 
concentration in the blood is greatly affected by season and lati-
tude as well as nutritional intake. This vitamin plays an essential 
role in absorbing calcium and phosphate, which are important 
to bone health. Vitamin D deficiency may lead to rickets in 
children or osteomalacia in adults [5]. Currently, no consensus 
exists about the threshold serum levels for defining vitamin D 
deficiency. Some studies have defined vitamin D deficiency as 
serum 25(OH)D levels <50  nmol/L6, while other studies and 
Public Health England recommendations have used 25(OH)D 
levels <25 nmol/L as their cutoff [7, 8]. To protect bone health, 
Public Health England recommends people taking 10 μg (400 
IU) of vitamin D every day in the winter [9].
In addition to bone health, some studies have shown that 
this vitamin may have some immunomodulatory effects and 
anti-infective potential. At a cellular level, some studies have 
shown that vitamin D regulates the production of the anti-
microbial peptide cathelicidin [10–13], and 1 study indi-
cated that vitamin D supplementation was associated with 
a decrease in HSV-1 viral load and mRNA expression in 
HSV-1-infected cells [14]. In addition, among epidemio-
logical studies, a meta-analysis showed that the risk of in-
fection was lower in chronic kidney disease patients with 
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normal or higher serum vitamin D levels [15], and another 
meta-analysis using original patient data from 25 random-
ized controlled trials showed that people receiving vitamin 
D supplementation had a lower risk of respiratory tract in-
fection [16].
However, whether vitamin D is associated with protection 
against herpesviruses is still unclear, and no comprehensive 
review exists of this possible association. As vitamin D sup-
plementation is an inexpensive public health intervention, 
studying its possible association with herpesviruses may help 
us find a novel approach to mitigate the health impact of these 
infectious diseases. We therefore undertook a systematic review 
to examine the relationship between serum vitamin D levels or 
oral vitamin D supplementation and the risk of infection with 
or reactivation of any of the 8 human herpesviruses.
METHODS
Protocol and Registration
The protocol of this study has been previously registered on 
PROSPERO (registration number: CRD42019130153) and 
published [17].
Eligibility Criteria
As previously described, we included only human studies in our 
review [17]. The exposures were serum vitamin D deficiency or 
oral vitamin D supplementation, including vitamin D analog 
treatment. Vitamin D deficiency was defined as serum 25(OH)
D <25 nmol/L, to be consistent with the Public Health England 
approach. The comparator for vitamin D–deficient partici-
pants was people with sufficient serum vitamin D levels, and 
the comparator for vitamin D supplementation was participants 
without vitamin D supplementation or a placebo group. The 
outcomes were infection or reactivation of any human herpes-
virus, confirmed based on physicians’ clinical diagnoses or by 
laboratory-based techniques such as polymerase chain reaction. 
For more rigorous causal estimation, only cohort, case–control, 
and intervention studies were eligible to be included.
Information Sources and Search
One researcher (L.Y.L.) searched 6 main databases and 4 gray 
literature databases. The main databases were Medline (Ovid), 
EMBASE (Ovid), Web of Science, Scopus, the Cochrane 
Library, and Global Health (Ovid). The gray literature data-
bases included Open Grey, BASE, EThOS, and the clinical trials 
register at ClinicalTrials.gov. The search was updated to August 
31, 2019.
The search strategy was reviewed and revised by a librarian. 
Synonyms of “human herpesviruses” and “vitamin D” were 
searched using both controlled vocabularies and keywords 
in different databases, in which subject headings were mod-
ified. The search results were combined using the Boolean 
logic operator “AND.” One author (L.Y.L.) also hand-searched 
the final included studies to identify potential eligible articles. 
Duplicated search results were removed using EndNote X9 [18].
Study Selection, Data Collection, and Data Items
The titles and abstracts of the included articles were independ-
ently screened by 2 researchers (L.Y.L. and K.B.), and the full 
texts of the eligible studies were further examined. Any dis-
crepancy in these processes was resolved by a third researcher 
(S.M.L.). Two researchers (L.Y.L. and K.B.) independently ex-
tracted data from the first 3 studies using a predefined form, 
and 1 researcher (L.Y.L.) extracted the other included arti-
cles. The complete data extraction form is available in the 
Supplementary Data. Briefly, data were extracted following the 
framework of population, exposure/intervention, comparator, 
and outcomes. In addition, study characteristics such as study 
design, study population, results, statistical analysis methods, 
and confounders were extracted. The numbers of subjects with 
outcomes were obtained for each exposure group, and the re-
ported crude results and adjusted results were recorded. If a 
study reported >1 vitamin D outcome, such as deficiency, in-
sufficiency, and sufficiency, only the outcomes of vitamin D de-
ficiency and sufficiency were extracted. For studies reporting 
continuous outcomes, their mean or median change of outcome 
and standard deviation were recorded. The authors of the in-
cluded studies were contacted for unclear or missing data.
Risk of Bias in Individual Studies
Predefined templates based on the Cochrane approach were 
used to assess the risk of bias in the included studies. For obser-
vational studies, 5 domains were assessed: confounding factors, 
selection of participants, misclassification of variables, bias due 
to missing data, and reverse causation. For intervention studies, 
bias was assessed using version 2 of the Cochrane risk-of-bias 
tool for randomized trials (RoB 2) to assess random sequence 
generation; allocation concealment; blinding of participants, 
personnel, and assessment; incomplete outcome data; and se-
lective reporting [19]. The assessment tools were piloted and 
tested, and the risk of bias of the first 3 included studies was as-
sessed by 2 independent researchers (L.Y.L. and K.B.) to ensure 
consistency and quality. One researcher (L.Y.L.) evaluated the 
risk of bias of the other studies. Discrepancies in the assessment 
were resolved by a third researcher (S.M.L. or C.W.G.).
Summary Measures
The results of the included studies were synthesized by vi-
tamin D exposure and by different herpesviruses using a nar-
rative approach. The main adjusted risk ratio (RR), hazard 
ratio (HR), or odds ratio (OR) was presented for each study. 
If the numbers of outcomes among exposure and compar-
ator groups were reported without an estimate of relative 
risk, the unadjusted risk ratio and 95% confidence interval 
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exposures, and outcomes, we further assessed their heter-
ogeneity and synthesized them using a meta-analysis. The 
heterogeneity between studies was assessed using I2, and a 
random-effects meta-analysis was used for substantial het-
erogeneity (I2 > 50%). A  funnel plot was used to evaluate 
publication bias [20]. All analysis was conducted using Stata, 
version 16/IC (StataCorp, College Station, TX, USA).
Risk of Bias Across Studies
For studies reporting similar exposures and outcomes, 
we further analyzed the risk of bias. The Grading of 
Recommendations, Assessment, Development and 
Evaluations (GRADE) framework was used to assess the 
overall quality of evidence [21]. The levels of confidence were 
established through the design of included studies, which 
were further downgraded or upgraded according to the do-
mains of risk of bias, inconsistency, indirectness, impreci-
sion, publication bias, strong association, dose response, and 
confounding. A  rank of “high,” “moderate,” “low,” or “very 
low” was given to the quality of evidence.
Patient Consent Statement
Patient consent is not required for publication. Ethical review is 
not required for a systematic review.
RESULTS
Study Characteristics
Figure  1 displays the steps to study selection. In our search, 
4537 articles were initially identified. After removing dupli-
cated studies, we scanned 2548 titles and abstracts. We excluded 
articles that did not meet our inclusion and exclusion criteria, 
and we reviewed the full text of 62 articles for eligibility.
Ten studies were finally included in our review, and their 
characteristics are summarized in Table 1. They were 8 cohort 
studies, 1 case–control study, and 1 randomized controlled 
trial. All cohort and case–control studies were undertaken in 
single-hospital settings, while the only randomized controlled 
trial used data from 5 hospitals in the Netherlands. All studies 
were conducted in different regions: 4 studies from Asia, 3 from 
Europe, 2 from North America, and 1 from Africa. All studies 
were conducted with patients with the following underlying 
Medline (Ovid): 369
EMBASE (Ovid): 1854
Global health (Ovid): 311
Scopus: 1111
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health conditions: end-stage renal disease requiring hemo-
dialysis (n = 1), organ transplants (n = 7), multiple sclerosis 
(n = 1), and HIV (n = 1). Seven included studies analyzed the 
association between serum vitamin D levels and herpesvirus 
infections, and the other 3 studies assessed the correlation be-
tween vitamin D supplementation and herpesviruses.
Among studies assessing serum vitamin D status and the 
risk of different herpesvirus infections or reactivation, the def-
inition of vitamin D deficiency varied. Five cohort studies de-
fined vitamin D deficiency as serum 25(OH)D below 20  ng/
mL or 50  nmol/L, 1 study used vitamin D levels <15  ng/mL 
(37.5 nmol/L), and the other used tertiles to classify its partici-
pants, with the mean vitamin D level in the lowest tertile being 
20.78 nmol/L.
Among studies of vitamin D supplementation and the risk of 
herpesviruses infection or reactivation, 2 used activated vitamin 
D analog (calcitriol or 1α-hydroxylated vitamin D) supplemen-
tation, and the other used inactive vitamin D3 (cholecalciferol) 
supplementation (Table 1).
Meta-analysis of Vitamin D Deficiency and the Risk of CMV Infection or 
Reactivation Among Patients With Organ Transplants
A random-effects meta-analysis was conducted to pool 6 ob-
servational studies, which analyzed the association between 
serum vitamin D deficiency and the risk of CMV disease after 
transplantation therapy. No evidence was found that serum vi-
tamin D deficiency increased the risk of CMV infection or re-
activation in patients receiving transplants (RR, 1.06; 95% CI, 
0.66–1.70) (Figure  2). The sample sizes of these studies were 
relatively small (Table 2), and the heterogeneity between studies 
was high (I2 = 55.4%). Five of the included studies did not ad-
just for confounding factors, and bias due to missing data was 
unclear in 2 studies (Table 3). Due to the high risk of bias and 
imprecise estimates of these studies, the overall quality of evi-
dence was low (Table 4). The funnel plot of the included studies 
showed a relatively symmetric pattern, which suggests that the 
risk of publication bias was low (Figure 3).
Vitamin D Deficiency and Herpesvirus Infection or Reactivation
One cohort study [22] also investigated whether vitamin D de-
ficiency was associated with the risk of developing herpes zoster 
after kidney transplantation, showing no evidence of associa-
tion (RR, 0.98; 95% CI, 0.337–2.87). Another study investigated 
the association between serum vitamin D levels and change in 
HHV-8 viral load among HIV-positive patients recruited from 
a trial [23]. It showed no evidence that inadequate vitamin D 
levels were associated with higher viral load in plasma (viral 
load decreased by 0.5 [0 to 1.5] log copies/mL in the inade-
quate vitamin D group and by 0.4 [0 to 1.5] log copies/mL in 
the adequate vitamin D group; P = .8) or in peripheral blood 
mononuclear cells (viral load decreased by 0.9 [–0.4 to 2.3] log 
copies/mL among the inadequate vitamin D group and by 1.0 [0 
to 2.0] log copies/mL in the adequate vitamin D group; P = .9) 
(Table 2). Nevertheless, both studies had a high risk of bias in at 
least 1 domain (Table 3).
Vitamin D Supplementation and the Risk of Herpesvirus Infection or 
Reactivation
One case–control study (n = 126) indicated that hemodial-
ysis patients receiving vitamin D supplementation had a lower 
risk of developing herpes zoster (OR, 0.06; 95% CI, 0.0–0.4) 
(Table 2) [24]. The assessed risk of bias in this study was mod-
erate in 1 domain (Table 3).
A historical cohort study assessed the association between vi-
tamin D supplementation before transplantation and the risk 
of CMV after transplantation [25]. The group unexposed to 
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Table 2.  Summary of Results
Author, Year
Population Size, No.; 
Mean/Median Follow-up 
Time, mo
Subjects With Outcome [or 
Exposure for Case–Control 
Studies], No. (%)
Statistical Analysis  
Method Used Main Reported Results Covariates Adjusted for:
Vitamin D deficiency
Serum vitamin D levels before transplantation and the risk of CMV infection after transplantation
Lee et al. (2014) n = 351; followed for 
12 mo




Sufficiency: n = 8/135 (5.9%)
Saber et al. (2015) n = 82; followed for  
4 mo




Sufficient: n = 7/12 (58%)
Ban et al. (2017) n = 174; median  
follow-up period 35.5 
mo
CMV infection: Low tertile: 
n = 3/59 (5.1%)
Not reported CMV: Not adjusted
High tertile: n = 9/58 (15.8%) Risk ratio, 0.328 (95% 
CI, 0.09–1.15) [cal-
culated by review 
authors]
Park et al. (2017) n = 164; followed for 
24.8 mo
Deficiency: n = 16/135 (11.9%) Not reported CMV: Not adjusted
Sufficiency: n = 2/29 (6.9%)  Risk ratio, 1.72 (95% CI, 
0.42–7.07) [calculated 
by review authors]
Astor et al. (2019) n = 1976; followed for 
12 mo





Age, sex, ethnicity, cause 
of ESKD, BMI, donor 
status, prior transplant, 
delayed graft function, 
induction immunosup-
pression, smoking status, 
HLA mismatch category, 
CMV serostatus, time 
from transplant to 25(OH)
D measurement, history 
of acute rejection, esti-
mated glomerular filtration 
rate category, season, 
maintenance immunosup-
pression, and quartile of 
calcineurin inhibitor level
Serum 25(OH)D <20 ng/




n = 215; followed up  
for at least 12 mo
Vitamin D deficiency: 
n = 34/135 (25.2%)
Not reported CMV: Not adjusted
No deficiency: 14/80 (17.5%)  Risk ratio, 1.44 (95% CI, 
0.82–2.51) [calculated 
by review authors]
Serum vitamin D levels before transplantation and the risk of herpes zoster after transplantation
Ban et al. (2017) n = 174; median follow-up 
period 35.5 mo
Herpes zoster: Not reported Herpes zoster: Not adjusted
Low tertile: n = 6/59 (10.2%)  Risk ratio, 0.98 (95% CI, 
0.337–2.87)  
[calculated by review 
authors]
High tertile: n = 6/58 (10.3%)
Serum vitamin D levels and the change of serum HHV-8 viral load
Erlandson et al. (2014) n = 85; followed for 24 
mo
Not applicable Mann-Whitney  
test
A decrease in HHV-8 
viral load (log), median 
(IQR): In plasma:
Not adjusted
• Inadequate: 0.5 (0–1.5)
• Adequate: 0.4 (0–1.5)
In PBMC:
• Inadequate: 0.4 (0–1.5)
• Adequate: 1.0 (0–2.0)
Vitamin D supplementation
Vitamin D supplementation and the risk of herpes zoster among dialysis patients
Chao et al. (2012) n = 126; followed at least 
1 mo before the event
Exposure among HZ cases: 






OR, 0.06 (95% CI, 
0.0–0.4)
Hepatitis or cirrhosis, ce-
rebrovascular accident, 
use of iron therapy, use 
of corticosteroids, use of 
statins, CRP, intact PTH, 
ferritin






/ofid/article/8/1/ofaa570/6043438 by guest on 02 February 2021
Systematic Review of Vitamin D and Herpesvirus • ofid • 7
vitamin D supplementation had a 2.3-fold increased hazard of 
developing CMV disease after transplantation (HR, 2.31; 95% 
CI, 1.44–3.71) (Table 2). However, the risk of misclassification 
in this study was moderate, and the risk of bias due to missing 
data was unclear (Table 3).
One randomized controlled trial assessed the effect of oral 
vitamin D supplementation on EBV viral load in blood [26], 
showing that high-dose vitamin D supplementation did not de-
crease the viral load in peripheral blood mononuclear cells or B 
cells (Table 2). However, the overall risk of bias of this interven-
tional study was high (Table 3).
DISCUSSION
We reviewed 10 studies examining serum vitamin D deficiency 
or vitamin D supplementation and the risk of herpesvirus in-
fection or reactivation among patients with comorbidities. The 
results showed no consistent association between serum vi-
tamin D deficiency and the risk of herpesvirus infection or re-
activation, but some evidence that vitamin D supplementation 
may be associated with a reduced risk of herpes zoster or CMV 
disease. However, the risk of bias of most included studies was 
high. Therefore, the evidence for establishing an association 
between vitamin D deficiency or oral vitamin D supplementa-
tion and the risk of herpesvirus infection or reactivation is still 
inconclusive.
Ours is the first systematic review of vitamin D and her-
pesvirus infection or reactivation. Some previous studies have 
also explored the various association between vitamin D defi-
ciency or vitamin D supplementation and similar chronic viral 
infections. Among patients with chronic hepatitis B virus in-
fection, a meta-analysis showed that serum vitamin D levels 
were negatively associated with hepatitis B viral load [27]. For 
hepatitis C virus patients, 1 meta-analysis reported that base-
line serum vitamin D was associated with a sustained virologic 
response to antiviral and interferon treatment [28], while 
another recent meta-analysis reported no association [29]. 
A previous systematic review found no clear evidence of an ef-
fect of vitamin D supplementation on HIV viral load [30]. The 
immunomodulatory mechanism of vitamin D is still unclear, 
and its potential for preventing clinical viral infections is also 
inconclusive. Due to the paucity of current literature, further 
research is needed.
Our meta-analysis found no evidence that vitamin D status af-
fected the risk of CMV infection or reactivation among patients 
receiving transplantation. CMV and other herpesviruses are the 
most common viral infections among transplant recipients [31]. 
However, the detected incidence of CMV will vary according to 
the use of prophylactic measures, differences in testing frequency, 
and definitions of CMV disease. These factors may have contrib-
uted to heterogeneity in our analysis. There were 2 studies that 
did not mention prophylactic measures [32, 33], and 1 study pro-
vided prophylactic antiviral treatment only for people with a high 
risk of CMV disease [34]. Two studies regularly checked parti-
cipants’ CMV viral loads [22, 25], and 3 studies only examined 
CMV antigen or viral load when patients were symptomatic [33–
35]. These inconsistencies may lead to different estimations of 
the risk of CMV infections. We suggest that future studies about 
vitamin D and CMV diseases consider using a standardized defi-
nition of CMV and a consistent follow-up approach [36], so that 
researchers can accurately estimate the association between vi-
tamin D and CMV infections among transplant patients.
While our study did not focus on the outcome of transplant 
rejection, there is a close relationship between CMV infection 
and graft injuries, which increase the risk of rejection [37, 38]. 
A recent systematic review also indicated that there was weak 
evidence showing an association between vitamin D deficiency 
and acute or chronic graft-vs-host disease (GVHD) [39]. While 
viral infections such as CMV may act as mediators of any rela-
tionship between vitamin D and graft loss, further research into 
these complex relationships is needed.
The effects of vitamin D supplementation on the risk of EBV 
remain inconclusive. The only included study did not find a 
Author, Year
Population Size, No.; 
Mean/Median Follow-up 
Time, mo
Subjects With Outcome [or 
Exposure for Case–Control 
Studies], No. (%)
Statistical Analysis  
Method Used Main Reported Results Covariates Adjusted for:
Moscarelli et al. (2016) n = 360; followed for 
12 mo
Nonuser group: n = 21 (9%); 








acute rejection, BKV in-
fection, CMV serostatus, 
steroid boluses, BMI
Vitamin D supplementation and change of EBV viral load in blood cells
Rolf et al. (2018) n = 53; followed for 7.3 
mo
Not applicable Mann-Whitney U 
test
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reduction in EBV viral load among multiple sclerosis patients 
randomized to receive high-dose vitamin D supplementa-
tion, but levels of antibody against EBV were reduced in this 
intervention group [26]. While this may provide some limited 
evidence for an immunomodulatory effect of vitamin D, it is 
unclear how well EBV antibodies reflect infection status, so fur-
ther studies are needed.
Because of the impairment of renal function in calcium and 
phosphate homeostasis, many CKD patients take vitamin D 
supplements for maintaining bone health [40]. One included 
study showed that taking vitamin D supplements reduced the 
risk of herpes zoster among CKD patients receiving hemodi-
alysis [24]. In this study, all participants were recruited before 
the introduction of zoster vaccine in Taiwan [41]. However, 
as zoster vaccinations can effectively reduce the risk of herpes 
zoster among older patients with CKD [42], future studies of 
the relationship between vitamin D and herpes zoster should 
take zoster vaccinations into account.
The studies included in our review have some limitations. 
First, 7 observational studies did not adjust for possible con-
founding factors, and they did not report herpesvirus infections 
as their main outcomes. In addition, the only included trial did 
not report the details of randomization or show a clear baseline 
characteristics table, so it was not possible to assess the effec-
tiveness of the randomization process. These unadjusted con-
founding factors may lead to a high risk of bias in assessing the 
association. According to the included studies that adjusted for 
potential confounders, some evidence existed that vitamin D 
supplementation may be associated with a decreased risk of 
CMV disease among transplantation patients and herpes zoster 
among dialysis patients [24, 25]. In addition, among patients 
who received organ transplants, vitamin D deficiency was asso-
ciated with a higher hazard of CMV disease after adjusting for 
confounders [35].
The inconsistent definition of vitamin D deficiency is another 
major limitation. Of 7 observational studies assessing vitamin D 
deficiency, 5 defined vitamin D deficiency as serum 25(OH)D 
<50 nmol/L (20 ng/mL), 1 defined it as 15 ng/mL (37.5 nmol/L), 
and the other used the lowest tertile as the exposure group, 
which was serum 25(OH)D <8.3 ng/mL (20.75 nmol/L). This 
significant difference in exposure definitions increases the het-
erogeneity between studies.
Another limitation is generalizability. The populations of the 
included studies were people with severe underlying conditions, 
Table 4. Quality of Evidence of Outcomes
No. of Studies Study Design Risk of Bias Inconsistency Indirectness Imprecision Publication Bias Other Considerations Quality
Outcomes: vitamin D deficiency/insufficiency associates with an increased risk of CMV infection
6 Observational study Serious Serious Not serious Serious Not serious None Very low
Abbreviation: CMV, Cytomegalovirus.
aHeterogeneity is substantial (I2 = 55.4%; P = .047).
.8
.3
Astor, B. C., et al. Ban, T. H., et al.
Lee,  J. R., et al.
Saber,  A., et al.
Upper Cl
Fernandez-Ruiz, M., et al.
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such as end-stage renal disease, organ transplantation, and HIV. 
Further, these studies were conducted in single-hospital set-
tings. Their results cannot be extrapolated to other populations 
with different comorbidities or even the general population. 
More studies among different populations are needed.
Our review has some strengths. This is the first review system-
ically examining the existing available evidence about vitamin D 
and herpesvirus infection. We comprehensively searched 6 major 
medical databases and 4 gray literature databases, and we sum-
marized the results and assessed the risk of bias using a prede-
fined framework. However, our study has some limitations. First, 
due to the paucity of studies, we were not able to review the asso-
ciation between vitamin D and some herpesvirus infections, such 
as HSV-1, HSV-2, HHV-6A, HHV-6B, and HHV-7. This may be 
caused by their difficulty in diagnosis. Second, because no guide-
line exists for defining serum 1,25-dihydroxycholecalciferol, 
an active metabolite of vitamin D, we were unable to include 
studies assessing this. Third, despite the comprehensiveness of 
our search, our search strategy may still have missed some eli-
gible studies. Although we did not limit the language for eligible 
studies, studies in other languages may not be able to be identi-
fied. Further reviews of the association between vitamin D and 
herpesviruses need to consider these limitations.
Based on currently available studies, some limited evidence sug-
gests that vitamin D supplementation may have a protective effect 
against herpes zoster in hemodialysis patients and CMV disease 
in renal transplant patients, but insufficient evidence supports any 
association between serum vitamin D deficiency and the risk of 
herpesvirus infection or reactivation. However, the current studies 
have focused solely on immunosuppressed patients with major 
underlying comorbidities, and some did not adjust for potential 
confounding factors. As vitamin D deficiency is not uncommon, 
for future studies, it is important to focus not only on individuals 
with specific comorbidities but also on the general population. 
In addition, future studies need to adopt consistent definitions 
of vitamin D deficiency, and adequately adjust for possible con-
founding factors, to provide robust evidence of any association be-
tween vitamin D and herpesvirus infection or reactivation.
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